Literature DB >> 25696794

Diagnostic and prognostic value of BCL2 rearrangement in 53 patients with follicular lymphoma presenting as primary skin lesions.

Anne Pham-Ledard1, Anne Cowppli-Bony2, Adélaïde Doussau2, Martina Prochazkova-Carlotti3, Elodie Laharanne4, Thomas Jouary5, Marc-Antoine Belaud-Rotureau3, Béatrice Vergier4, Jean-Philippe Merlio4, Marie Beylot-Barry6.   

Abstract

OBJECTIVES: To study the diagnostic value of BCL2 rearrangement in follicle center lymphoma (FCL) presenting as primary skin lesions, evaluate its prevalence and the prognostic value in primary cutaneous FCL (PCFCL), and assess prognostic factors in PCFCL.
METHODS: Fifty-three patients with a cutaneous presentation of FCL without a history of nodal lymphoma were selected retrospectively. Clinical and histologic data were collected together with staging and follow-up data. A fluorescence in situ hybridization (FISH) test for BCL2 split probes was performed on skin biopsy specimens.
RESULTS: Initial staging procedures identified 47 PCFCLs and six cases of secondary skin involvement of FCL (SSIFCL). FISH detected seven cases carrying a BCL2 rearrangement: four (8.5%) of 47 PCFCLs and three (50%) of six SSIFCLs. These seven cases coexpressed BCL2 and CD10. In PCFCL, cutaneous relapse rate was 42.6%. A small/medium centrocytic cell population was associated with a higher probability of skin relapse in univariate (P = .008) and multivariate (P = .028) analysis, and BCL2 rearrangement detection was associated with secondary extracutaneous spreading (P = .05).
CONCLUSIONS: We observed that BCL2 rearrangement in PCFCL is rare, associated with initial positivity of staging (diagnostic value) or with secondary extracutaneous spreading (prognostic value). In selected cases with BCL2-CD10 coexpression, FISH testing could detect patients with poor outcome and require closer monitoring. Copyright© by the American Society for Clinical Pathology.

Entities:  

Keywords:  BCL2 rearrangement; FISH; Follicular lymphoma; Primary cutaneous follicle center lymphoma; Translocation t(14;18)

Mesh:

Substances:

Year:  2015        PMID: 25696794     DOI: 10.1309/AJCP4SUBR4NPSPTN

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  10 in total

1.  Concomitant 1p36 deletion and TNFRSF14 mutations in primary cutaneous follicle center lymphoma frequently expressing high levels of EZH2 protein.

Authors:  Ambrus Gángó; Bence Bátai; Martin Varga; Dóra Kapczár; Gergő Papp; Márta Marschalkó; Enikő Kuroli; Tamás Schneider; Judit Csomor; András Matolcsy; Csaba Bödör; Ágota Szepesi
Journal:  Virchows Arch       Date:  2018-06-01       Impact factor: 4.064

2.  Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locus.

Authors:  E Leich; E Hoster; M Wartenberg; M Unterhalt; R Siebert; K Koch; W Klapper; M Engelhard; B Puppe; H Horn; A M Staiger; C Stuhlmann-Laeisz; H W Bernd; A C Feller; M Hummel; D Lenze; H Stein; S Hartmann; M L Hansmann; P Möller; W Hiddemann; M Dreyling; G Ott; A Rosenwald
Journal:  Leukemia       Date:  2015-12-01       Impact factor: 11.528

Review 3.  Update in Diagnosis and Management of Primary Cutaneous B-Cell Lymphomas.

Authors:  Amanda Krenitsky; Skylar Klager; Leigh Hatch; Carlos Sarriera-Lazaro; Pei Ling Chen; Lucia Seminario-Vidal
Journal:  Am J Clin Dermatol       Date:  2022-07-19       Impact factor: 6.233

Review 4.  New developments in the pathology of malignant lymphoma: a review of literature published from January 2015 to April 2015.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2015-06-17       Impact factor: 0.196

5.  Genomic landscape of cutaneous follicular lymphomas reveals 2 subgroups with clinically predictive molecular features.

Authors:  Xiaolong Alan Zhou; Jingyi Yang; Kimberly G Ringbloom; Maria Estela Martinez-Escala; Kristen E Stevenson; Alexander T Wenzel; Damiano Fantini; Haley K Martin; Andrea P Moy; Elizabeth A Morgan; Shannon Harkins; Christian N Paxton; Bo Hong; Erica F Andersen; Joan Guitart; David M Weinstock; Lorenzo Cerroni; Jaehyuk Choi; Abner Louissaint
Journal:  Blood Adv       Date:  2021-02-09

6.  Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers.

Authors:  Marco Lucioni; Emilio Berti; Luca Arcaini; Giorgio A Croci; Aldo Maffi; Catherine Klersy; Gaia Goteri; Carlo Tomasini; Pietro Quaglino; Roberta Riboni; Mariarosa Arra; Elena Dallera; Vieri Grandi; Mauro Alaibac; Antonio Ramponi; Sara Rattotti; Maria Giuseppina Cabras; Silvia Franceschetti; Giulio Fraternali-Orcioni; Nicola Zerbinati; Francesco Onida; Stefano Ascani; Maria Teresa Fierro; Serena Rupoli; Marcello Gambacorta; Pier Luigi Zinzani; Nicola Pimpinelli; Marco Santucci; Marco Paulli
Journal:  Cancer Med       Date:  2016-09-26       Impact factor: 4.452

Review 7.  Practical aspects of NGS-based pathways analysis for personalized cancer science and medicine.

Authors:  Ekaterina A Kotelnikova; Mikhail Pyatnitskiy; Anna Paleeva; Olga Kremenetskaya; Dmitriy Vinogradov
Journal:  Oncotarget       Date:  2016-08-09

8.  [Primary cutaneous follicle center cell lymphoma: a case report and literatures review].

Authors:  J Qiao; R N Lu; L Wang; M Y Song; Z Wang; Z H Zhang; J Y Li; W Xu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2018-04-14

9.  BCL-2 Expression in Primary Cutaneous Follicle Center B-Cell Lymphoma and Its Prognostic Role.

Authors:  Alessandro Pileri; Claudio Agostinelli; Clara Bertuzzi; Vieri Grandi; Vincenza Maio; Irene Lastrucci; Marco Santucci; Nicola Pimpinelli
Journal:  Front Oncol       Date:  2020-04-28       Impact factor: 6.244

10.  Sites of extranodal involvement are prognostic in patients with stage 1 follicular lymphoma.

Authors:  Aditi Shastri; Murali Janakiram; Ioannis Mantzaris; Yiting Yu; Jaime S Londono; Amit K Verma; Stefan K Barta
Journal:  Oncotarget       Date:  2017-07-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.